Conclusions
In conclusion, this analysis showed that BWL at the end of cycle 1 of treatment was associated with unfavorable survival outcomes in patients with mGC/GEJC in the TAGS trial, regardless of FTD/TPI or placebo treatment. As observed in earlier settings [